Kathryn R. Byrne

Dr. Whitney Hendrickson is a specialized urogynecologist dedicated to women's health. She focuses on both medical and surgical treatments for pelvic organ prolapse, urinary incontinence, and fecal incontinence. She offers minimally invasive robotic surgery for prolapse and sacral neuromodulation for conditions like urgency incontinence, fecal incontinence, and urinary retention.Dr. Hendrickson, who works in the Division of Urogynecology and Pelvic Reconstructive Surgery at the University of Utah Health, is currently accepting new patients with pelvic floor disorders.Dr. Hendrickson earned her medical degree from the University of Massachusetts and completed her Obstetrics & Gynecology residency at UC San Diego. She then pursued advanced training with a fellowship in Urogynecology and Pelvic Reconstructive Surgery (formerly called Female Pelvic Medicine and Reconstructive Surgery) at Duke University.In addition to her clinical work, Dr. Hendrickson is involved in quality improvement, clinical research, and medical education. She is the founder and chair of the Gynecology Quality Improvement and Patient Safety Committee, aimed at improving surgical outcomes for all gynecologic surgeries at the University of Utah.Her research is aimed at improving treatment outcomes for pelvic floor disorders, mostly focused on overactive bladder and lower urinary tract symptoms. She has developed tools to help both patients and clinicians make informed treatment decisions, particularly in managing urgency urinary incontinence and predicting post-surgical complications.As a Eunice Kennedy Shriver National Institute of Child Health and Human Development Women’s Reproductive Health Research (WRHR) K12 scholar, she is studying the outcomes of treatments for urgency urinary incontinence, including OnabotulinumtoxinA (BOTOX®) and sacral neuromodulation (SNM) to understand who will respond best to which therapy. She is also involved in medical student and resident education mostly focusing on surgical didactics.

Dr. Fair received his medical degree from Albany Medical College, completed his Pediatric residency at UT Southwestern in Austin at Dell Children´s Hospital, and his Pediatric Hematology/ Oncology Fellowship here at the University of Utah. He also received additional training in Clinical Research through the Masters of Science in Clinical Investigation Program at the University of Utah. He has also received a Utah Certificate of Palliative Education (UCoPE). Dr. Fair joined the University of Utah faculty in 2016 and is currently an Associate Professor of Pediatrics in the Division of Hematology/ Oncology. Dr. Fair serves as the Director of the Primary Children’s Hospital Solid Tumor Program. He also is the Founder and Medical Director of the Childhood, Adolescent, and Young Adult (AYA) Cancer Survivorship Program at Primary Children’s Hospital. He serves as the Director of the Huntsman Cancer Institute AYA Program and as the co-Medical Director of the Huntsman Intermountain Adolescent and Young Adult Program (HIAYA). He is the Founder and co-Medical Director of the University of Utah, Primary Children’s Hospital, and Huntsman Cancer Institute’s Oncofertility Programs. He also co-Founded and served for over 5 years as the Associate Director of the Primary Children’s Hospital Supportive Oncology for Adolescents and Pediatrics Program (SOAP). At the national level, Dr. Fair has served on numerous committees and steering committees. Some of these include serving on the steering committees for the Soft Tissue Sarcoma Group and Rare Tumor Group within the Children’s Oncology Group (COG). He also served as a member of the AYA Responsible Investigator (RI) Group within COG. He currently serves on many National Comprehensive Cancer Network (NCCN) AYA Guideline Committees, and has previously served on the NCCN Neuroblastoma Guideline Committee and the Wilm's Tumor Committee. He is also a leader in the Oncofertility Consortium. He also serves on advisory boards for numerous non-profit and philanthropic organizations benefiting pediatric and AYA cancer causes. Dr. Fair has also been active in advocating for gaps in insurance coverage for cancer patients, playing a lead role in changing policy at the insurance provider and legislative level. Dr. Fair´s research interests include improving survival outcomes for children and AYAs diagnosed with solid tumors, specifically clinical trial development for sarcomas and rare tumors. He is also involved in research investigating improved outcomes and care for survivors of pediatric and AYA cancer. Another area of research is the gonadal and fertility function of cancer survivors, and the understanding of the gonadal toxic and gonadal protective agents in cancer therapy

Con Yee Ling, M.D. is an Associate Professor in the Division of Neonatology at the University of Utah, School of Medicine. She is the Medical Director of Primary Children's Newborn ICU and the Neonatal Quality Director for Intermountain's Obstetrics and Newborn Operations. She provides neonatology services at three facilities, the Neonatal Intensive Care Unit (NICU) at University of Utah Hospital, Primary Children’s Hospital and Intermountain Medical Center. Among her responsibilities is educating Pediatric Residents, Neonatology Fellows and Neonatal Nurse Practitioners.